Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 20;24(6):5858.
doi: 10.3390/ijms24065858.

Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review

Katarzyna Król  1 , Anna Mazur  1 , Paulina Stachyra-Strawa  2 , Ludmiła Grzybowska-Szatkowska  2
Affiliations
Review

Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review

Katarzyna Król et al. Int J Mol Sci. .

Abstract

Lung cancer is the leading cause of death worldwide for both men and women. Surgery can be offered as a radical treatment at stages I and II and selected cases of stage III (III A). Whereas at more advanced stages, combined modalities of treatment are applied: radiochemotherapy (IIIB) and molecularly targeted treatment (small molecule tyrosine kinase inhibitors, VEGF receptor inhibitors, monoclonal antibodies, and immunological treatment with monoclonal antibodies). Combination treatment, composed of radiotherapy and molecular therapy, is increasingly employed in locally advanced and metastatic lung cancer management. Recent studies have indicated a synergistic effect of such treatment and modification of immune response. The combination of immunotherapy and radiotherapy may result in the enhancement of the abscopal effect. Anti-angiogenic therapy, in combination with RT, is associated with high toxicity and should be not recommended. In this paper, the authors discuss the role of molecular treatment and the possibility of its concurrent use with radiotherapy in non-small cell lung cancer (NSCLC).

Keywords: EGFR; NSCLC; PD-1; PD-L1; VEGFR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Casal-Mouriño A., Ruano-Ravina A., Lorenzo-Gonzalez M., Rodrigues-Martinez A., Giraldo-Osorio A., Varela-Lema L., Pereiro-Brea T., Barros-Dios J.M., Valdes-Cuadrado L., Perez-Rios M. Epidemiology of stage III lung cancer: Frequency, diagnostic characteristics, and survival. Transl. Lung Cancer Res. 2021;10:506–518. doi: 10.21037/tlcr.2020.03.40. - DOI - PMC - PubMed
    1. Krzakowski M., Jassem J., Antczak A., Chorostowska-Wynimko J., Dziadziuszko R., Głogowski M., Tomasz G., Dariusz K., Włodzimierz O., Tadeusz O. Cancer of the lung, pleura and mediastinum. Oncol. Clin. Pract. 2022;18:20–50.
    1. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742. doi: 10.1016/S1470-2045(11)70184-X. - DOI - PubMed
    1. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246. doi: 10.1016/S1470-2045(11)70393-X. - DOI - PubMed
    1. Nagano T., Tachihara M., Nishimura Y. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Curr. Cancer Drug Targets. 2019;19:595–630. doi: 10.2174/1568009619666181210114559. - DOI - PubMed